Norway’s sovereign wealth fund is among investors renouncing a revamp of the board of directors at Danish obesity-drug maker Novo Nordisk A/S.
Bloomberg - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Company
Trending
Categories
© Bloombergnews. All rights resereved